A Randomized, Double-Blind, Placebo-Controlled Phase II Study of CI-994 or Placebo in Combination withPaclitaxel and Carboplatin in First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/016/30/06

Funding

  • Pfizer Inc.: $42,900.00